secwatch.observer — SEC 8-K summary
======================================

Issuer:     ALUMIS INC. (ALMS)
CIK:        0001847367
Form:       8-K
Filed at:   2025-03-04T23:59:59+00:00
Accession:  0001104659-25-020039
Event type: m_and_a
Sentiment:  positive
Materiality: 0.70
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Alumis and ACELYRIN reaffirm all-stock merger; pro forma cash ~$737M
--------------------------------------------------------------------

- Alumis and ACELYRIN reaffirm commitment to merge in an all-stock transaction expected to close Q2 2025.
- Pro forma cash of ~$737M as of Dec 31, 2024 provides runway into 2027.
- Alumis had ~$289M cash, ACELYRIN ~$448M (preliminary, each as of Dec 31, 2024).
- Combined portfolio includes ESK-001 (psoriasis, lupus), lonigutamab (thyroid eye disease), A-005 (multiple sclerosis).
- Transaction subject to stockholder approvals and customary closing conditions.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1847367/000110465925020039/0001104659-25-020039-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1847367/000110465925020039/tm258190d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-020039

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer